Retatrutide before and after: the trial numbers
In the 48-week Phase 2 obesity trial, adults taking 12 mg of retatrutide lost an average of 24.2% of their body weight — about 58 pounds for the average participant — versus roughly 2% on placebo. That’s the largest average weight loss published for any obesity medication, and it’s the entire reason this drug is famous before it’s approved.
What you won’t find on this page is a photo gallery. Retatrutide can’t be legally prescribed or bought in the US, which means every “before and after” image circulating online came from an unverifiable source. The trial data is the only evidence anyone can actually check, so that’s what we show.
What the results looked like over time
Two features of the Phase 2 curve stand out, and both are worth understanding before you read anything into a photo.
Weight came off early and kept coming off. Loss began within the first weeks of dosing and, unusually, had not clearly flattened by week 48 — most obesity drugs show a visible plateau well before that. Whether it eventually levels off, and where, is one of the things Phase 3 is designed to answer over its longer 68–80 week windows (⚠ verify durations against the current TRIUMPH records).
Results tracked with dose. Lower trial arms produced meaningfully less weight loss than 12 mg, so “retatrutide results” isn’t a single number — it’s a dose–response curve, and the headline figure sits at the top of it. The dosage page walks through the arms.
| Trial | Dose | Duration | Avg. weight loss | Studied in |
|---|---|---|---|---|
| Phase 2 (obesity) | 12 mg | 48 weeks | 24.2% (~58 lb) | Adults with obesity, no diabetes |
| TRIUMPH-1 | Up to 12 mg | 80 weeks | ~24% ⚠ | Adults with obesity (Phase 3) |
| TRIUMPH-4 | Up to 12 mg | 80 weeks | ~26% ⚠ (~64 lb ⚠) | Obesity with knee osteoarthritis (Phase 3) |
What “before and after” leaves out
An average is not a promise, and a percentage isn’t a picture. Three things shape what any individual result would look like:
- Trial conditions came with the trial. Participants had structured diet and activity guidance, regular visits, and clinician contact through every dose increase. Those supports are part of the result, not a footnote to it.
- The range around the average was wide. Some participants lost far more than 24%, some far less, and some stopped early because of side effects. Reporting only the mean flatters the picture.
- Weight isn’t only fat. Rapid loss on this drug class takes lean mass with it unless resistance training and protein intake are deliberate — which is why what the scale says and what a photo shows can diverge. Our supplement stack guide covers the protective side of that.
How it compares to what’s available now
Across separate trials — never head-to-head — retatrutide’s 24.2% sits above tirzepatide’s roughly 21% (SURMOUNT-1, 72 weeks) and semaglutide’s roughly 15% (STEP-1, 68 weeks) (⚠ verify both comparison figures and durations). Cross-trial comparisons are directional at best: different populations, different lengths, different protocols.
The comparison that actually matters is availability. Tirzepatide is approved, prescribable, and produces the largest weight loss of any drug you can start this month. Retatrutide produces a bigger number in a study you can’t join on demand.
Why online before-and-after photos can’t be verified
This is the part most pages skip, and it’s the reason the photos are worth so little.
Even setting aside outright fabrication, the mechanics defeat verification. Photos don’t carry a lot number, a purity assay, a dose log, or a control group. A grey-market vial with no identity or purity assurance could contain the wrong compound, the wrong amount, or nothing active at all — and the person posting has no way to know either. That’s before you get to lighting, posture, timing, and the ordinary selection bias of only ever seeing the results that went well.
Published trial data has the opposite properties: a defined population, a placebo arm, a fixed protocol, independent review, and figures anyone can check against the source. That’s why this page shows numbers instead of pictures.
Results you can actually get today
If the 24% figure is what brought you here, the useful comparison is what an approved drug does under a prescriber’s supervision — with a real product, a verified dose, and someone accountable for the outcome.
Retatrutide: the complete guide How the triple agonist works, trial results, the approval timeline, and how to join a trialThis page is informational and is not medical advice. Retatrutide is an investigational drug that is not approved by the FDA and cannot be legally prescribed or purchased in the US. Trial figures describe supervised study participants, not expected individual results. See our medical disclaimer.